Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CodeBreaK 100 sotorasib in KRAS p.G12C-mutant advanced solid tumors and NSCLC
2024-511798-31-00Phase 2Completed
- Sponsor
- Amgen
- Start
- Apr 2024
- Modality
- Small Molecules
- Countries
- 15
01
Overview
Phase 2, open-label trial of sotorasib in Nonhematologic neoplasms, non-small cell lung cancer (NSCLC) and colorectal cancer (CRC) (9 arms), sponsored by Amgen. Started Apr 2024; status: completed.
02
Drugs
sotorasib
03
Conditions
Nonhematologic neoplasmsnon-small cell lung cancer (NSCLC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2024-511798-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511798-31-00.